| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PZP |
| Uniprot No | P20742 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 603-829aa |
| 氨基酸序列 | MKPEAELSVSSVYNLLTVKDLTNFPDNVDQQEEEQGHCPRPFFIHNGAIY VPLSSNEADIYSFLKGMGLKVFTNSKIRKPKSCSVIPSVSAGAVGQGYYG AGLGVVERPYVPQLGTYNVIPLNNEQSSGPVPETVRSYFPETWIWELVAV NSSGVAEVGVTVPDTITEWKAGAFCLSEDAGLGISSTASLRAFQPFFVEL TMPYSVIRGEVFTLKATVLNYLPKCIRAEGIEQEKTFSSMTCASGANVSE QLSLKLPSNVVKESARASFSVLGDILGSAMQNIQNLLQMPYGCGEQNMVL FAPNIYVLNYLNETQQLTQEIKAKAVGYLITGYQRQLNYKHQDGSYSTFG |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PZP(孕激素相关子宫内膜蛋白)重组蛋白的模拟参考文献示例(仅供参考，具体文献需通过学术数据库验证)：
---
1. **文献名称**：*"Recombinant PZP as a Potential Immunocontraceptive Agent: Expression and Functional Characterization"*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统表达重组PZP蛋白，验证其免疫原性及在动物模型中诱导抗生育抗体的能力，探讨其作为避孕疫苗的潜力。
2. **文献名称**：*"Structural Analysis of Recombinant PZP and Its Interaction with Progesterone"*
**作者**：Chen L, et al.
**摘要**：利用X射线晶体学解析重组PZP的三维结构，揭示其与孕激素结合的活性位点，为研究其在子宫内膜生理中的作用提供分子基础。
3. **文献名称**：*"Recombinant PZP Modulates T-cell Response in Autoimmune Disorders: In Vitro and In Vivo Evidence"*
**作者**：Wang Y, et al.
**摘要**：证明重组PZP可通过调节Treg细胞活性抑制小鼠模型中的自身免疫反应，提示其在免疫治疗中的应用前景。
4. **文献名称**：*"High-Yield Production of Biologically Active Recombinant PZP in Mammalian Cell Systems"*
**作者**：Kumar R, et al.
**摘要**：优化哺乳动物细胞表达系统(如CHO细胞)以提高重组PZP产量，并验证其与天然蛋白相似的糖基化修饰和生物功能。
---
**注意**：以上文献信息为模拟示例，实际研究中请通过 **PubMed、Web of Science 或 Google Scholar** 检索真实文献。建议结合关键词“recombinant PZP protein”、“progesterone-associated endometrial protein”等进行精准查询。
**Background of PZP Recombinant Protein**
PZP (Pregnancy Zone Protein), a member of the α₂-macroglobulin protease inhibitor family, is a high-molecular-weight glycoprotein primarily associated with pregnancy. It is produced in the liver and placenta, with elevated levels observed during gestation, inflammation, and certain malignancies. Structurally, PZP shares homology with other protease inhibitors, featuring a "bait region" that traps proteases, modulating immune and inflammatory responses by regulating extracellular matrix degradation and cytokine activity.
Interest in recombinant PZP stems from its dual role in immunomodulation and tissue remodeling. Studies suggest PZP suppresses maternal immune responses to fetal antigens, preventing rejection during pregnancy. This property has spurred exploration in transplant immunology and autoimmune therapies. Additionally, PZP interacts with growth factors (e.g., TGF-β) and matrix metalloproteinases (MMPs), implicating it in cancer progression and wound healing.
Recombinant PZP is engineered using mammalian expression systems (e.g., CHO cells) to ensure proper glycosylation and functional conformation. Its applications span diagnostic tools (e.g., monitoring pregnancy complications) and therapeutic development, including targeted drug delivery and anti-inflammatory biologics. Recent research also highlights its potential as a biomarker for cancers (e.g., ovarian, breast) and neurodegenerative diseases.
Despite progress, challenges persist in understanding its pleiotropic mechanisms and optimizing production for clinical use. Ongoing studies aim to elucidate PZP's signaling pathways and refine recombinant variants with enhanced stability and specificity, positioning it as a versatile candidate for next-generation biologics.
×
